Understanding the Biliary Tract Cancer (BTC) Patient Journey:
Multistakeholder Perspectives for Improved Outcomes

• Release Date: December 1, 2025
• Expiration Date: May 31, 2027
• Estimated Time to Complete Activity: 0.75 hour
• Compatible with all modern browsers and mobile devices
• For additional information about the accreditation of this activity, please visit https://partnersed.com

Learn About:

• The epidemiology, pathophysiology, and burdens of BTC
• HER2 amplification and the impact of HER2 expression
• Best practices for payer management of BTC cancers
• The role of patient navigation in improving care delivery and outcomes in BTC

Expert Faculty Presenters

Melinda Bachini Chief Patient Officer Cholangiocarcinoma Foundation Click here for biography Ryan Haumschild, PharmD, MS, MBA, CPEL Vice President of Pharmacy Emory Healthcare and Winship Cancer Institute Click here for biography Shubham Pant, MD Professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine University of Texas MD Anderson Cancer Center Click here for biography

Target Audience

The primary target audience for this initiative consists of medical directors, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations. Other managed care professionals include nurses, case managers, policy administrators, utilization managers, C-suite executives, and IT professionals.

Statement of Need/Program Overview

Biliary tract cancer (BTC) is a heterogeneous disease with poor prognosis. It represents a global health issue with high tumor-related mortality.

Precision oncology provides a long-anticipated strategy to improve care, control costs, and reduce waste in cancer care. However, realizing these benefits is subject to overcoming barriers impacting the timeliness of care for patients which may be impeded by operational inefficiencies, limited biomarker testing, and delays in starting targeted treatments. Managed care professionals have a key role in supporting the timely and appropriate treatment of BTC. This clinical primer can equip managed care professionals with baseline knowledge to navigate treatment decisions and support timely treatment for patients with BTC.

Educational Objectives 
After completing this activity, the participant should be better able to:

• Review the epidemiology, pathophysiology, and burdens of BTC
• Recognize HER2 amplification and the impact of HER2 expression on treatment decisions in BTC
• Identify best practices for payer management of BTC cancers, especially in community care settings
• Evaluate common barriers across the patient journey and the role of patient navigation in improving care delivery and outcomes in BTC

Accreditation Information

Joint Accreditation Statement In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and Impact Education, LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Interprofessional Continuing Education (IPCE)
This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.

Physician Continuing Medical Education
Partners designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits^™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Partners designates this continuing education activity for 0.75 contact hours (0.75 CEUs) of the Accreditation Council for Pharmacy Education.

UAN: JA4008073-9999-25-358-H01-P
Activity Type: Knowledge

Continuing Nursing Credit
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hours.

DISCLOSURE OF CONFLICTS OF INTEREST
Partners for Advancing Clinical Education (Partners) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to Partners policy. Partners is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

FEE INFORMATION
There is no fee for this educational activity.